Healthcare Industry News: Cytogen
News Release - July 29, 2008
The DNA Repair Company Strengthens Operations and Development Capabilities with Addition of Two Senior OfficialsIndustry Veterans to Bring Wealth of R&D, Operations and Commercialization Experience to Emerging Cancer Diagnostic Company
BOSTON--(HSMN NewsFeed)--The DNA Repair Company (DNAR), an emerging company focused on personalized approaches to cancer treatment, announced today the expansion of its management team with the appointments of Brian E. Ward, Ph.D. as executive vice president and Stella Quan, Ph.D. as senior director of product development. Dr. Ward most recently served as senior vice president for Genomic Health, Inc. Dr. Quan joins the company from bioMerieux Inc., where she was director of immunoassay development.
“The addition of Brian and Stella to the DNAR management team greatly bolsters our capabilities and depth as a company in operations and clinical development,” said Daniel Paterson, president and CEO of DNAR, Inc. “This is an exciting time for our company and we expect Stella and Brian to play pivotal roles in our advancement of new and innovative diagnostic tools and in the emergence of DNAR as the leading personalized medicine company in oncology.”
Dr. Ward brings more than two decades of clinical laboratory development, operations and commercialization expertise to DNAR, having successfully developed and directed the creation of several highly profitable clinical laboratories and led commercialization efforts for numerous clinical genetics, genomics and forensics products. Dr. Ward will be responsible for oversight of the development and commercialization of DNAR’s personalized medicine products. Prior to his tenure at Genomics Health, Dr. Ward served as senior vice president of medical genetic services and senior vice president of operations at Myriad Genetic Laboratories, Inc. and has also held positions at Genzyme Genetics and The University of Colorado. A Founding Fellow of the American College of Medical Genetics, Dr. Ward holds a Masters Degree in Genetic Counseling, a Ph.D. in Human Genetics and is boarded in Molecular Genetics and Cytogenetics.
Dr. Quan joins DNAR with more than 25 years of management, research, development and securing regulatory approval for biomarkers in the biotechnology and diagnostic industries. Dr. Quan will lead the development, regulatory and validation efforts for DNAR’s personalized medicine products. Prior to her most recent position at bioMerieux, Dr. Quan served as the senior director of operations at Tripath Oncology. Earlier in her career, Dr. Quan held a variety of research and development positions of increasing responsibility at Chiron Corporation, including senior director of diagnostic product development for blood screening and diagnostics business, as well as the director of Chiron Reference Laboratory. Dr. Quan received her Bachelor of Science degree in Chemistry from the University of California, Berkeley and her Ph.D. in Biochemistry from Massachusetts of Technology.
DNAR is leveraging its deep knowledge of the role that DNA repair pathways play in cancer to create new tools that give physicians unprecedented data-driven insights into which course of treatment will work most effectively for an individual patient. DNAR aims to improve patient care by improving physicians’ ability to prescribe the most effective treatments the first time from the host of therapeutic options available. DNAR is advancing a major goal of personalized medicine – to identify the right therapy for the right patient, and to reduce the need for “trial and error” medicine.
Source: DNA Repair Company
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.